Table 2.

Response and Toxicity Outcomes

		Group 1a	Group 2b
Selected variables	rs11614913	n (%)	n (%)	P	OR (95% CI)c
Response
	CT+TT	51 (11.5)	240 (54.3)		1.00 (reference)
	CC	23 (5.2)	101 (22.9)	0.66	0.88 (0.50–1.55)
Leukocytopenia
	CT+TT	228 (51.6)	69 (15.6)		1.00 (reference)
	CC	95 (21.5)	35 (7.9)	0.35	1.25 (0.78–2.02)
Neutropenia
	CT+TT	235 (53.2)	41 (9.3)		1.00 (reference)
	CC	102 (23.1)	24 (5.4)	0.18	1.48 (0.84–2.61)
Anemia
	CT+TT	265 (60.0)	15 (3.4)		1.00 (reference)
	CC	123 (27.8)	7 (1.6)	0.96	1.00 (0.39–2.57)
Thrombocytopenia
	CT+TT	269 (60.9)	16 (3.6)		1.00 (reference)
	CC	120 (27.2)	10 (2.3)	0.57	1.27 (0.55–2.92)
Hematologic toxicity
	CT+TT	189 (42.8)	83 (18.8)		1.00 (reference)
	CC	81 (18.3)	46 (10.4)	0.23	1.32 (0.84–2.01)
Gastrointestinal toxicity
	CT+TT	262 (59.3)	16 (3.6)		1.00 (reference)
	CC	111 (25.1)	11 (2.5)	0.21	1.72 (0.75–3.95)
Overall toxicity
	CT+TT	176 (39.6)	88 (19.8)		1.00 (reference)
	CC	63 (14.3)	54 (12.2)	0.02d	1.73 (1.10–2.71)

^aGroup 1 for response means complete response or partial response, for toxicities means any grade 1 or 2 toxicities.

^bGroup 2 for response means stable disease or progressive disease, for toxicities means any grade 3 or 4 toxicities.

^cData were calculated by unconditional logistic regression, adjusting covariates for (i) response were age, gender, type of treatment regimen, tumor/node/metastasis (TNM) stage, performance status (PS), and histological type, (ii) anemia were PS, type of treatment regimen, and TNM stag, as TNM was a potential confounder for anemia, (iii) gastrointestinal toxicity were PS, gender, and type of treatment regimen, as gender was a potential confounder for gastrointestinal toxicity, (iv) other toxicities were PS and type of treatment regimen.

^dData of statistical significance.

OR, odds ratios; CI, confidence intervals.